These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17914664)

  • 1. Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats.
    Yassen A; Olofsen E; Kan J; Dahan A; Danhof M
    Pharm Res; 2008 Jan; 25(1):183-93. PubMed ID: 17914664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics.
    Yassen A; Olofsen E; Dahan A; Danhof M
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1136-49. PubMed ID: 15701707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers.
    Yassen A; Olofsen E; Romberg R; Sarton E; Teppema L; Danhof M; Dahan A
    Clin Pharmacol Ther; 2007 Jan; 81(1):50-8. PubMed ID: 17185999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats.
    Yassen A; Kan J; Olofsen E; Suidgeest E; Dahan A; Danhof M
    J Pharmacol Exp Ther; 2006 Nov; 319(2):682-92. PubMed ID: 16855177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats.
    Chevillard L; Mégarbane B; Risède P; Baud FJ
    Toxicol Lett; 2009 Dec; 191(2-3):327-40. PubMed ID: 19819313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models.
    Andresen T; Upton RN; Foster DJ; Christrup LL; Arendt-Nielsen L; Drewes AM
    Basic Clin Pharmacol Toxicol; 2011 Apr; 108(4):274-84. PubMed ID: 21138531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers.
    Yassen A; Olofsen E; van Dorp E; Sarton E; Teppema L; Danhof M; Dahan A
    Clin Pharmacokinet; 2007; 46(11):965-80. PubMed ID: 17922561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid-induced respiratory effects: new data on buprenorphine.
    Dahan A
    Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats.
    Yassen A; Kan J; Olofsen E; Suidgeest E; Dahan A; Danhof M
    J Pharmacol Exp Ther; 2007 May; 321(2):598-607. PubMed ID: 17283225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats.
    Dahan A; Yassen A; Bijl H; Romberg R; Sarton E; Teppema L; Olofsen E; Danhof M
    Br J Anaesth; 2005 Jun; 94(6):825-34. PubMed ID: 15833777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of respiratory depression induced by the combination of buprenorphine and diazepam in rats.
    Vodovar D; Chevillard L; Caillé F; Risède P; Pottier G; Auvity S; Mégarbane B; Tournier N
    Br J Anaesth; 2022 Mar; 128(3):584-595. PubMed ID: 34872716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine.
    Sarton E; Teppema L; Dahan A
    Adv Exp Med Biol; 2008; 605():486-91. PubMed ID: 18085322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of buprenorphine on fentanyl withdrawal in rats.
    Bruijnzeel AW; Marcinkiewcz C; Isaac S; Booth MM; Dennis DM; Gold MS
    Psychopharmacology (Berl); 2007 May; 191(4):931-41. PubMed ID: 17211652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
    Ciraulo DA; Hitzemann RJ; Somoza E; Knapp CM; Rotrosen J; Sarid-Segal O; Ciraulo AM; Greenblatt DJ; Chiang CN
    J Clin Pharmacol; 2006 Feb; 46(2):179-92. PubMed ID: 16432270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration.
    Robertson SA; Lascelles BD; Taylor PM; Sear JW
    J Vet Pharmacol Ther; 2005 Oct; 28(5):453-60. PubMed ID: 16207308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers.
    Yassen A; Olofsen E; Romberg R; Sarton E; Danhof M; Dahan A
    Anesthesiology; 2006 Jun; 104(6):1232-42. PubMed ID: 16732095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Analgesic Patches in Cynomolgus Macaques (
    Smith AA; Halliday LC; Lindeblad MO; Fortman JD
    J Am Assoc Lab Anim Sci; 2019 May; 58(3):356-361. PubMed ID: 31010456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The concentration-effect relationship of the respiratory depressant effects of alfentanil and fentanyl.
    Mildh LH; Scheinin H; Kirvelä OA
    Anesth Analg; 2001 Oct; 93(4):939-46. PubMed ID: 11574361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol.
    Cichewicz DL; Welch SP; Smith FL
    Eur J Pharmacol; 2005 Nov; 525(1-3):74-82. PubMed ID: 16288738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.